DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8v3nhr/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Hepatitis C Overview
- Therapeutics Development
- Pipeline Products for Hepatitis C - Overview
- Pipeline Products for Hepatitis C - Comparative Analysis
- Hepatitis C - Therapeutics under Development by Companies
- Hepatitis C - Therapeutics under Investigation by Universities/Institutes
- Hepatitis C - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Hepatitis C - Products under Development by Companies
- Hepatitis C - Products under Investigation by Universities/Institutes
- Hepatitis C - Companies Involved in Therapeutics Development
Companies Mentioned - Partial List
- 3-V Biosciences, Inc.
- AbbVie Inc.
- Altor BioScience Corporation
- Amarillo Biosciences, Inc.
- Amarna Therapeutics B.V.
- ARA Healthcare Pvt. Ltd.
- Arbutus Biopharma Corporation
- Arrowhead Research Corporation
- Astex Pharmaceuticals, Inc.
- Benitec Biopharma Limited
- BIOCAD
- Biogenomics Limited
- BioLineRx, Ltd.
- Bionor Pharma ASA
- Biota Pharmaceuticals, Inc.
- Biotest AG
- Biotron Limited
- Boehringer Ingelheim GmbH
- Bolder Biotechnology, Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Cocrystal Pharma, Inc.
- Conatus Pharmaceuticals Inc.
- Debiopharm International S.A.
- DEKK-TEC, Inc.
- Delpor, Inc.
- Digna Biotech, S.L.
- DiscoveryBiomed, Inc.
- Enanta Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Formune S.L.
- Genecode AS
-
GeneCure LLC
For more information visit http://www.researchandmarkets.com/research/8v3nhr/hepatitis_c